KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) EBIT (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of EBIT readings, the most recent being $1.9 billion for Q1 2026.

  • On a quarterly basis, EBIT rose 8.57% to $1.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $7.9 billion, a 6.81% increase, with the full-year FY2025 number at $7.7 billion, up 5.57% from a year prior.
  • EBIT hit $1.9 billion in Q1 2026 for Thermo Fisher Scientific, down from $2.3 billion in the prior quarter.
  • In the past five years, EBIT ranged from a high of $2.8 billion in Q2 2022 to a low of $1.6 billion in Q2 2023.
  • Median EBIT over the past 5 years was $1.9 billion (2023), compared with a mean of $1.9 billion.
  • Biggest five-year swings in EBIT: crashed 44.59% in 2023 and later increased 15.34% in 2024.
  • Thermo Fisher Scientific's EBIT stood at $1.9 billion in 2022, then decreased by 0.38% to $1.9 billion in 2023, then rose by 8.74% to $2.0 billion in 2024, then rose by 11.86% to $2.3 billion in 2025, then decreased by 17.38% to $1.9 billion in 2026.
  • The last three reported values for EBIT were $1.9 billion (Q1 2026), $2.3 billion (Q4 2025), and $1.9 billion (Q3 2025) per Business Quant data.